Hostname: page-component-745bb68f8f-5r2nc Total loading time: 0 Render date: 2025-01-14T19:39:29.889Z Has data issue: false hasContentIssue false
  • English
  • Français

Bromocriptine in Parkinson’s Disease: Results Obtained With High and Low Dose Therapy

Published online by Cambridge University Press:  18 September 2015

J. David Grimes
J. David Grimes*
Affiliation:
Parkinson’s Disease Clinic, Division of Neurology, Ottawa Civic Hospital, University of Ottawa
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The results obtained with high and low dose bromocriptine therapy were compared in a review assessing the per cent of patients showing improvement (not taking account of the extent of improvement). It is concluded that the response rate with low dose bromocriptine is as good as that obtained with high dose therapy for both de novo and levodopa treated patients. The incidence of adverse effects is similar in the high and low dose treatment groups: More levodopa reduction results in a higher daily bromocriptine requirement. A statistical analysis of 61 bromocriptine-levodopa treated patients showed no positive correlation between bromocriptine dose and severity or duration of Parkinson’s disease.

Type
7. Treatment of Parkinson’s Disease
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue S1: Current Concepts and Controversies in Parkinson’s Disease , February 1984 , pp. 225 - 228
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Calne, DB, Teychenne, PF, Claveria, LE, Eastman, R, Greenacre, JK, Petrie, A (1974a) Bromocriptine in Parkinsonism. Br Med J 4:442–444.CrossRefGoogle ScholarPubMed
Calne, DB, Teychenne, PF, Leigh, PN, Bamji, AN, Greenacre, JK (1974b) Treatment of Parkinsonism with bromocriptine. Lancet 2:1355.CrossRefGoogle ScholarPubMed
Calne, DB (1978) Dopaminergic agonists in the treatment of Parkinsonism. Clin NeuroPharm 3:153–166.CrossRefGoogle Scholar
Caraceni, TA, Celano, I, Parati, E, Girotti, F (1977) Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 40:1142–1146.CrossRefGoogle ScholarPubMed
Duvoisin, RC, Mendoza, MM, Yahr, MD (1980) A comparative study of bromocriptine and levodopa in Parkinson’s disease. Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. Eds Goldstein, Met al. 271–275. Raven Press, New York.Google Scholar
Fahn, S, Cote, LJ, Barrett, RE, Snider, SR (1980) Further experiences with low doses of bromocriptine in Parkinson’s disease. Ergot Compound and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. Eds Goldstein, Met al. 255–259. Raven Press, New York.Google Scholar
Glantz, R, Goetz, CG, Nausieda, PA, Weiner, WJ, Klawans, HL (1981) The effect of bromocriptine (BCT) on the On-off phenomenon. J Neural Trans 52:41–47.Google ScholarPubMed
Grimes, JD, Hassan, MN (1981) Method of bromocriptine addition to the drug regime of patients with advanced Parkinson’s disease. Can J Neurol Sci 8:31–34.CrossRefGoogle Scholar
Grimes, JD, King, DB, Kofman, OS, Molina-Negro, P, Wilson, AF, Bouchard, S (1983a) The use of low dose bromocriptine to treat end-of-dose failure in levodopa treated Parkinson’s disease patients: The results of a Multi-Centre study. Can J Neurol Sci 10:132.Google Scholar
Grimes, JD, Delgado, MR, Gray, P (1983b) Low dose bromocriptine therapy in “De Novo” Parkinson’s disease: Indications, dosage, initial response rate, and adverse effects. Neurology 33(2): 112.Google Scholar
Hoehn, MM, Yahr, MD (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17:427–442.CrossRefGoogle ScholarPubMed
Hoehn, MM (1981) Bromocriptine and Its use in Parkinsonism. J Am Geriatr Soc 29(6):251–258.CrossRefGoogle ScholarPubMed
Kartzinel, R, Shoulson, I, Calne, DB (1976a) Studies with bromocriptine Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism. Neurology 26:511–513.CrossRefGoogle ScholarPubMed
Kartzinel, R, Teychenne, P, Gillespie, MM, Perlow, M, Gielen, AC, Sadowsky, DA, Calne, DB (1976b) Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 7:272–275.CrossRefGoogle Scholar
Koller, WC, Weiner, WJ, Nausieda, PA, Klawans, HL (1979) Bromocriptine: Decreased clinical effects at higher doses. Neurology 29:1439.CrossRefGoogle Scholar
Larsen, TA, Newman, RP, LeWitt, PA, Calne, DB (1983) Bromocriptine dosageand the severity of Parkinson’s disease. Neurology 33(2): 137.Google Scholar
LeWitt, PA, Calne, DB (1981) Recent advances in the treatment of Parkinson’s disease: The role of bromocriptine. J Neural Trans 51:175–184.CrossRefGoogle Scholar
Lieberman, A, Kupersmith, M, Estey, E.Goldstein, M (1976a) Treatment of Parkinson’s disease with bromocriptine. New Engl J Med 25:1400–1403.CrossRefGoogle Scholar
Lieberman, A, Zolfaghari, M, Boal, D, Hassouri, H, Vogel, B, Battista, A.Fuxe, K, Goldstein, M (1976b) The antiparkinsonian efficacy of bromocriptine. Neurology 26:405–409.CrossRefGoogle ScholarPubMed
Parkes, JD, Marsden, CD, Donaldson, I.Galea-Debono, A, Walters, J, Kennedy, G, Asselman, P (1976) Bromocriptine treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 39:184–193.CrossRefGoogle ScholarPubMed
Quinn, N, Illas, A, Lhermitte, F, Agid, Y (1981) Bromocriptine and domperidone in the treatment of Parkinson’s disease. Neurology 31:662–667.CrossRefGoogle Scholar
Rinne, UK, Marttila, R (1978) Brain Dopamine Receptor Stimulation and the Relief of Parkinsonism: Relationship between bromocriptine and levodopa. Ann Neurol 4:263–267.CrossRefGoogle ScholarPubMed
Stem, GM, Lees, AJ (1983) Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson’s disease. Adv Neurol 37:17–21.Google Scholar
Teychenne, PF, Leigh, PN, Reid, JL, Calne, DB, Greenacre, JK, Petrie, A (1975) Idiopathic parkinsonism treated with bromocriptine. Lancet 2:473–476.CrossRefGoogle ScholarPubMed
Teychenne, PF, Pfeiffer, RF, Bern, SM, McInturff, D, Calne, DB (1978) Comparison between lergotrile and bromocriptine in parkinsonism. Ann Neurol 3:319–324.CrossRefGoogle ScholarPubMed
Teychenne, PF, Bergsrud, D, Racy, A, Elton, RL, Vern, B (1982) Bromocriptine: Low-dose therapy in Parkinson disease. Neurology 32:577–583.CrossRefGoogle ScholarPubMed